These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
133 related articles for article (PubMed ID: 33659046)
1. Quercetin shortened survival of radio-resistant B-1 cells Ramos YAL; Souza OF; Novo MCT; Guimarães CFC; Popi AF Oncotarget; 2021 Feb; 12(4):355-365. PubMed ID: 33659046 [TBL] [Abstract][Full Text] [Related]
2. Systemic in vivo lentiviral delivery of miR-15a/16 reduces malignancy in the NZB de novo mouse model of chronic lymphocytic leukemia. Kasar S; Salerno E; Yuan Y; Underbayev C; Vollenweider D; Laurindo MF; Fernandes H; Bonci D; Addario A; Mazzella F; Raveche E Genes Immun; 2012 Feb; 13(2):109-19. PubMed ID: 21881595 [TBL] [Abstract][Full Text] [Related]
3. The New Zealand black mouse as a model for the development and progression of chronic lymphocytic leukemia. Salerno E; Yuan Y; Scaglione BJ; Marti G; Jankovic A; Mazzella F; Laurindo MF; Despres D; Baskar S; Rader C; Raveche E Cytometry B Clin Cytom; 2010; 78 Suppl 1(Suppl 1):S98-109. PubMed ID: 20839343 [TBL] [Abstract][Full Text] [Related]
4. Alterations in the mir-15a/16-1 Loci Impairs Its Processing and Augments B-1 Expansion in De Novo Mouse Model of Chronic Lymphocytic Leukemia (CLL). Kasar S; Underbayev C; Hassan M; Ilev I; Degheidy H; Bauer S; Marti G; Lutz C; Raveche E; Batish M PLoS One; 2016; 11(3):e0149331. PubMed ID: 26959643 [TBL] [Abstract][Full Text] [Related]
5. Role of mir-15a/16-1 in early B cell development in a mouse model of chronic lymphocytic leukemia. Underbayev C; Kasar S; Ruezinsky W; Degheidy H; Schneider JS; Marti G; Bauer SR; Fraidenraich D; Lightfoote MM; Parashar V; Raveche E; Batish M Oncotarget; 2016 Sep; 7(38):60986-60999. PubMed ID: 27533467 [TBL] [Abstract][Full Text] [Related]
6. Effects of miRNA-15 and miRNA-16 expression replacement in chronic lymphocytic leukemia: implication for therapy. Cutrona G; Matis S; Colombo M; Massucco C; Baio G; Valdora F; Emionite L; Fabris S; Recchia AG; Gentile M; Neumaier CE; Reverberi D; Massara R; Boccardo S; Basso L; Salvi S; Rosa F; Cilli M; Zupo S; Truini M; Tassone P; Calabrese M; Negrini M; Neri A; Morabito F; Fais F; Ferrarini M Leukemia; 2017 Sep; 31(9):1894-1904. PubMed ID: 28053325 [TBL] [Abstract][Full Text] [Related]
7. Evaluation of MiR-15a and MiR-16-1 as prognostic biomarkers in chronic lymphocytic leukemia. Braga TV; Evangelista FCG; Gomes LC; Araújo SSDS; Carvalho MDG; Sabino AP Biomed Pharmacother; 2017 Aug; 92():864-869. PubMed ID: 28599250 [TBL] [Abstract][Full Text] [Related]
8. MicroRNAs 15A and 16-1 Activate Signaling Pathways That Mediate Chemotaxis of Immune Regulatory B cells to Colorectal Tumors. Liu R; Lu Z; Gu J; Liu J; Huang E; Liu X; Wang L; Yang J; Deng Y; Qian J; Luo F; Wang Z; Zhang H; Jiang X; Zhang D; Qian J; Liu G; Zhu H; Qian Y; Liu Z; Chu Y Gastroenterology; 2018 Feb; 154(3):637-651.e7. PubMed ID: 29031499 [TBL] [Abstract][Full Text] [Related]
9. miR-181a/b significantly enhances drug sensitivity in chronic lymphocytic leukemia cells via targeting multiple anti-apoptosis genes. Zhu DX; Zhu W; Fang C; Fan L; Zou ZJ; Wang YH; Liu P; Hong M; Miao KR; Liu P; Xu W; Li JY Carcinogenesis; 2012 Jul; 33(7):1294-301. PubMed ID: 22610076 [TBL] [Abstract][Full Text] [Related]
10. ABT-737 resistance in B-cells isolated from chronic lymphocytic leukemia patients and leukemia cell lines is overcome by the pleiotropic kinase inhibitor quercetin through Mcl-1 down-regulation. Russo M; Spagnuolo C; Volpe S; Tedesco I; Bilotto S; Russo GL Biochem Pharmacol; 2013 Apr; 85(7):927-36. PubMed ID: 23353698 [TBL] [Abstract][Full Text] [Related]
12. H-2z homozygous New Zealand mice as a model for B-cell chronic lymphocytic leukemia: elevated bcl-2 expression in CD5 B cells at premalignant and malignant stages. Okamoto H; Nishimura H; Shinozaki A; Zhang D; Hirose S; Shirai T Jpn J Cancer Res; 1993 Dec; 84(12):1273-8. PubMed ID: 7507474 [TBL] [Abstract][Full Text] [Related]
13. Correcting miR-15a/16 genetic defect in New Zealand Black mouse model of CLL enhances drug sensitivity. Salerno E; Scaglione BJ; Coffman FD; Brown BD; Baccarini A; Fernandes H; Marti G; Raveche ES Mol Cancer Ther; 2009 Sep; 8(9):2684-92. PubMed ID: 19723889 [TBL] [Abstract][Full Text] [Related]
14. Loss of MIR15A and MIR16-1 at 13q14 is associated with increased TP53 mRNA, de-repression of BCL2 and adverse outcome in chronic lymphocytic leukaemia. Lin K; Farahani M; Yang Y; Johnson GG; Oates M; Atherton M; Douglas A; Kalakonda N; Pettitt AR Br J Haematol; 2014 Nov; 167(3):346-55. PubMed ID: 25040181 [TBL] [Abstract][Full Text] [Related]
15. Genomics of chronic lymphocytic leukemia microRNAs as new players with clinical significance. Calin GA; Croce CM Semin Oncol; 2006 Apr; 33(2):167-73. PubMed ID: 16616063 [TBL] [Abstract][Full Text] [Related]
16. Autologous T cells control B-chronic lymphocytic leukemia tumor progression in human-->mouse radiation chimera. Shimoni A; Marcus H; Dekel B; Shkarchi R; Arditti F; Shvidel L; Shtalrid M; Bucher W; Canaan A; Ergas D; Berrebi A; Reisner Y Cancer Res; 1999 Dec; 59(23):5968-74. PubMed ID: 10606243 [TBL] [Abstract][Full Text] [Related]
17. Blockage of Wnt/β-catenin signaling by quercetin reduces survival and proliferation of B-1 cells in vitro. Novo MC; Osugui L; dos Reis VO; Longo-Maugéri IM; Mariano M; Popi AF Immunobiology; 2015 Jan; 220(1):60-7. PubMed ID: 25245014 [TBL] [Abstract][Full Text] [Related]
18. Abnormal microRNA-16 locus with synteny to human 13q14 linked to CLL in NZB mice. Raveche ES; Salerno E; Scaglione BJ; Manohar V; Abbasi F; Lin YC; Fredrickson T; Landgraf P; Ramachandra S; Huppi K; Toro JR; Zenger VE; Metcalf RA; Marti GE Blood; 2007 Jun; 109(12):5079-86. PubMed ID: 17351108 [TBL] [Abstract][Full Text] [Related]
19. The pleiotropic flavonoid quercetin: from its metabolism to the inhibition of protein kinases in chronic lymphocytic leukemia. Russo GL; Russo M; Spagnuolo C Food Funct; 2014 Oct; 5(10):2393-401. PubMed ID: 25096193 [TBL] [Abstract][Full Text] [Related]